Formamido and carboxyamido compounds which can be retained in brain
    5.
    发明授权
    Formamido and carboxyamido compounds which can be retained in brain 失效
    可以保留在脑中的甲酰氨基和羧酰氨基化合物

    公开(公告)号:US5580904A

    公开(公告)日:1996-12-03

    申请号:US211304

    申请日:1994-06-24

    摘要: According to the present invention, a novel compound group which can pass through blood-brain barrier (BBB) with carrying a drug thereon and stay within brain to release the drug and a well-known compound group having the properties described above are provided.The compound represented by the general formula ##STR1## wherein, R.sup.1 represents C.sub.1-6 alkyl which may be substituted by a group selected from hydroxyl, carboxyl, amino group which may be substituted by C.sub.1-6 alkyl, and a five- to seven-membered saturated heterocyclic ring,R.sup.2 represents hydrogen or C.sub.1-6 alkyl,R.sup.3 represents hydrogen or C.sub.1-6 alkyl which may be substituted by hydroxyl,R.sup.4 represents hydrogen or C.sub.1-6 alkyl,R.sup.5 represents an amino acid residue, or --S--R.sup.6 or --CO--R.sup.6 wherein R.sup.6 represents C.sub.1-14 alkyl which may be substituted by a five- to seven-membered saturated ring; C.sub.2-6 alkenyl; aryl; or a five- to seven-membered saturated ring; or the group represented by the general formula (IVa): ##STR2## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the same meanings as defined above, and.multidot..multidot..multidot..multidot..multidot..multidot..multidot..multidot..multidot. represents a single bond or a double bondprovided that at least one of R.sup.1, R.sup.3 and R.sup.5 contains hydroxyl, carboxyl or amino, and a salt thereof.

    摘要翻译: PCT No.PCT / JP93 / 01075 Sec。 371日期:1994年6月24日 102(e)1994年6月24日PCT 1993年7月30日PCT公布。 公开号WO94 / 03424 日本1994年2月17日根据本发明,可以通过血脑屏障(BBB)携带药物并保持在脑内以释放药物的新型化合物组和具有所述性质的公知化合物组 提供以上。 由通式(Ia)表示的化合物,其中,R 1表示可被选自羟基,羧基,可被C 1-6烷基取代的氨基的基团取代的C 1-6烷基, 至7元饱和杂环,R 2表示氢或C 1-6烷基,R 3表示氢或可被羟基取代的C 1-6烷基,R 4表示氢或C 1-6烷基,R 5表示氨基酸残基,或 - S-R6或-CO-R6,其中R6表示可被5至7元饱和环取代的C 1-14烷基; C 2-6烯基; 芳基; 或五至七元饱和环; 或由通式(IVa)表示的基团:其中R 1,R 2,R 3和R 4具有与上述相同的含义,并且+ E,uns xxxxxxxxx + EE表示单键或双键 条件是R 1,R 3和R 5中的至少一个含有羟基,羧基或氨基,及其盐。

    Amorphous substance of tricyclic triazolobenzazepine derivative
    6.
    发明授权
    Amorphous substance of tricyclic triazolobenzazepine derivative 失效
    三环三氮苯并氮杂衍生物的无定形物质

    公开(公告)号:US07229985B2

    公开(公告)日:2007-06-12

    申请号:US10500071

    申请日:2002-12-25

    CPC分类号: C07D487/04

    摘要: Disclosed are 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine, which has been rendered amorphous and possesses improved absorption and dissoluvability, and a pharmaceutical composition comprising the same. Also disclosed are processes for producing 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine, which has been rendered amorphous, and a pharmaceutical composition comprising the same.

    摘要翻译: 公开了2-(1-异丙氧基羰基氧基-2-甲基丙基)-7,8-二甲氧基-4(H),10-二氧代-2H-YY =“S” 已经变成无定形且具有改善的吸收和溶解性的2,3-三唑并[4,5-c] [1]苯并氮杂,以及包含该组合物的药物组合物。 还公开了制备2-(1-异丙氧基羰基氧基-2-甲基丙基)-7,8-二甲氧基-4(5-UYYY =“S”)的方法,10-二氧代-2

    Amorphous substance of tricyclic triazolobenzazepine derivative
    7.
    发明申请
    Amorphous substance of tricyclic triazolobenzazepine derivative 失效
    三环三氮苯并氮杂衍生物的无定形物质

    公开(公告)号:US20050130955A1

    公开(公告)日:2005-06-16

    申请号:US10500071

    申请日:2002-12-25

    CPC分类号: C07D487/04

    摘要: Disclosed are 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine, which has been rendered amorphous and possesses improved absorption and dissoluvability, and a pharmaceutical composition comprising the same. Also disclosed are processes for producing 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H), 10-dioxo-2H-1,2, 3-triazolo[4,5-c][1]benzazepine, which has been rendered amorphous, and a pharmaceutical composition comprising the same.

    摘要翻译: 公开了2-(1-异丙氧基羰基氧基-2-甲基丙基)-7,8-二甲氧基-4(H),10-二氧代-2H-YY =“S” 已经变成无定形且具有改善的吸收和溶解性的2,3-三唑并[4,5-c] [1]苯并氮杂,以及包含该组合物的药物组合物。 还公开了制备2-(1-异丙氧基羰基氧基-2-甲基丙基)-7,8-二甲氧基-4(5-UYYY =“S”)的方法,10-二氧代-2